ClinicalTrials.gg
CompletedNCT00308438Updated May 14, 2021

Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease Who Completed Protocol CL0600-008

A Phase 2 interventional study of Teduglutide (ALX-0600) in Crohn's Disease, sponsored by Shire. Completed at 24 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-14.

Sponsored by Shire (part of Takeda) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 6 months after the study started (first participant enrolled Mar 2004, registered Sep 2005).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
67
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 86 studies in Crohn Disease by Takeda — 12 open to participants now, 14 under way, 7 of them phase 3. Crohn Disease · Takeda.

Enrollment
31st of 51
67 · median 100
Started
2004
the only one that year
Phase 2
13 of 86
3 open now
Registered
2nd of 86
by date

Among the 86 studies in Crohn Disease by Takeda, this one is the 31st largest by enrollment of the 51 interventional ones that give a count, is the only one that started in 2004, is one of 13 in phase 2, and was the 2nd registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

12 of the 86 studies in Crohn Disease by Takeda are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies in Crohn Disease by Takeda, or all of them as a file.
02

Study summary

The purpose of the study is to determine whether an investigational compound, ALX-0600, is safe and effective in treating Crohn's Disease.

Read the detailed description

The study is sixteen weeks in duration and there are twelve weeks of once-daily injections into your abdomen or thigh. There are a total of five visits.

03

Conditions studied

  • Crohn's Disease

Browse trials for

Keywords

  • Crohn Disease
  • Crohn's Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must have completed participation in the Pilot Active Crohn's Disease Study.
  • Subjects must continue to meet all inclusion criteria for Pilot Active Crohn's Disease Study with the following exceptions:

    • CDAI score greater than 220
    • Stool samples not required
    • C-reactive protein levels are not an exclusion criterion

Exclusion criteria

Exclusion Criteria:

  • Subject must continue to meet all exclusion criteria for Pilot Active Crohn's Disease Study with the following exceptions:

    • Participation in a clinical study of an experimental drug or device within 30 days before signing consent.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    1

    All subjects in the study dosed at 0.1 mg/kg teduglutide

    Drug: Teduglutide (ALX-0600)

Interventions

06

What researchers measure

Primary outcomes

  1. The percentage of subjects who are in remission (CDAI score less than 150) at week 12 of this study.

    Time frame: 12 weeks after start of study

Secondary outcomes

  1. The percentage of subjects (of those who achieved response in CL0600-008) who, at week 12 of this study, maintain the response they previously achieved.

    Time frame: 12 weeks after study start

  2. The percentage of subjects who did not respond in CL0600-008 who do respond at week 12 in this study

    Time frame: 12 weeks after study start

07

Study locations

24 sites
  • Advanced Clinical Therapeutics
    Tucson, Arizona 85712, United States
  • Rocky Mountain Gastroenterology
    Lakewood, Colorado 80401, United States
  • Rx Trials
    Washington, District of Columbia 20010, United States
  • Clinical Trials Management of Boca Raton
    Boca Raton, Florida 33486, United States
  • Clinical Research of West Florida
    Clearwater, Florida 33765, United States
  • Venture Research
    North Miami Beach, Florida 33162, United States
  • Pinnacle Trials
    Atlanta, Georgia 30329, United States
  • Saint Joseph's Health System
    Atlanta, Georgia 30342, United States
  • Northwestern University School of Medicine
    Chicago, Illinois 60619, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • Long Island Clinical Research Associates
    Great Neck, New York 11021, United States
  • Asher Kornbluth, MD, PC
    New York, New York 10128, United States
  • Wake Research Associates
    Raleigh, North Carolina 27612, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Lynn Health Science Institute
    Oklahoma City, Oklahoma 73112, United States
  • Atilla Ertan
    Houston, Texas 77005, United States
  • University of Utah
    Salt Lake City, Utah 84132, United States
  • McGuire DVAMC
    Richmond, Virginia 23249, United States
  • Dean Foundation Research Center
    Madison, Wisconsin 53715, United States
  • Vancouver General Hospital
    Vancouver, British Columbia V5Z 1L5, Canada
  • Health Sciences Center
    Winnipeg, Manitoba R3A 1R9, Canada
  • Queen Elizabeth II Health Sciences
    Halifax, Nova Scotia B3H 1V7, Canada
  • Life Screening Centres
    Toronto, Ontario M5S 2A5, Canada
08

References and documents

Publications

  • Buchman AL, Katz S, Fang JC, Bernstein CN, Abou-Assi SG; Teduglutide Study Group. Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease. Inflamm Bowel Dis. 2010 Jun;16(6):962-73. doi: 10.1002/ibd.21117. PubMed 19821509 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2004 to primary completion in Nov 2005, 20 months.

Of 56 industry-sponsored phase 2 interventional studies under Crohn Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 20 months is below that.

Counting every sponsor, half of 83 studies reached it within 34 months; a quarter within 23 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2005
First posted
Mar 29, 2006
StartActual
Mar 1, 2004
Primary completionActual
Nov 1, 2005
CompletionActual
Jun 1, 2006
Last update
May 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00308438
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Mar 29, 2006
Start date
Mar 1, 2004
Primary completion
Nov 1, 2005
Completion
Jun 1, 2006
Last update
May 14, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teduglutide

Start the discussion